Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab alone and with nivolumab in advanced solid tumors
NL-OMON54526Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of relatlimab and nivolumab in Nonhematologic neoplasms, melanoma, non-small cell lung cancer (NSCLC) and 7 more (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety, Dose-limiting toxicities and 3 more. Started Dec 2016; status: recruiting.
02
Drugs
relatlimabnivolumab
03
Conditions
Nonhematologic neoplasmsmelanomanon-small cell lung cancer (NSCLC)head and neck cancer (HNC)gastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON54526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54526.